The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease

被引：1
|
作者：
Kawada, Tomoyuki [1 ]
机构：
[1] Nippon Med Sch, Dept Hyg & Publ Hlth, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan
来源：
CLINICAL AND EXPERIMENTAL NEPHROLOGY | 2016年 / 20卷 / 01期
关键词：
Estimated glomerular filtration rate; Autosomal dominant polycystic kidney disease; Tolvaptan; Validity;
D O I：
10.1007/s10157-015-1134-y
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [41] Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
    Rodriguez-Espinosa, Diana
    Jesus Broseta, Jose
    Bastida, Carla
    Isabel Alvarez-Mora, Maria
    Nicolau, Carlos
    Alvarez, Cristina
    Agraz-Pamplona, Irene
    Sanchez-Baya, Maya
    Furlano, Monica
    Ruiz, Cesar
    Quintana, Luis F.
    Pineiro, Gaston J.
    Poch, Esteban
    Torra-Balcells, Roser
    Blasco, Miquel
    NEPHRON, 2023, 147 (3-4) : 152 - 157
  • [42] Creatine Kinase Elevation in Patients with Autosomal Dominant Polycystic Kidney Disease on Tolvaptan Treatment
    Rodriguez-Espinosa, Diana
    Payan, Elena C.
    Guillen, Elena
    Blasco Pelicano, Josep Miquel
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 393 - 393
  • [43] Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease
    Akihisa, Taro
    Manabe, Shun
    Kataoka, Hiroshi
    Makabe, Shiho
    Yoshida, Rie
    Ushio, Yusuke
    Watanabe, Kentaro
    Sato, Masayo
    Tsuchiya, Ken
    Mochizuki, Toshio
    Nitta, Kosaku
    KIDNEY360, 2021, 2 (07): : 1148 - 1151
  • [44] Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease
    Irazabal, Maria V.
    Torres, Vicente E.
    Hogan, Marie C.
    Glockner, James
    King, Bernard F.
    Ofstie, Troy G.
    Krasa, Holly B.
    Ouyang, John
    Czerwiec, Frank S.
    KIDNEY INTERNATIONAL, 2011, 80 (03) : 295 - 301
  • [45] Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function
    Boertien, Wendy E.
    Meijer, Esther
    de Jong, Paul E.
    ter Horst, Gert J.
    Renken, Remco J.
    van der Jagt, Eric J.
    Kappert, Peter
    Ouyang, John
    Engels, Gerwin E.
    van Oeveren, Willem
    Struck, Joachim
    Czerwiec, Frank S.
    Oberdhan, Dorothee
    Krasa, Holly B.
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (06) : 833 - 841
  • [46] Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease?
    Horie, Shigeo
    KIDNEY INTERNATIONAL, 2015, 88 (01) : 14 - 16
  • [47] Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
    Rodney D. Gilbert
    Hazel Evans
    Kazeem Olalekan
    Arvind Nagra
    Mushfequr R. Haq
    Mark Griffiths
    Pediatric Nephrology, 2017, 32 : 893 - 896
  • [48] Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease
    van Dijk, MA
    Kamper, AM
    van Veen, S
    Souverijn, JHM
    Blauw, GJ
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (11) : 2152 - 2157
  • [49] Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?
    Hartung, Erum A. A.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (01): : 11 - 13
  • [50] Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Edwards, Marie E.
    Chebib, Fouad T.
    Irazabal, Maria V.
    Ofstie, Troy G.
    Bungum, Lisa A.
    Metzger, Andrew J.
    Senum, Sarah R.
    Hogan, Marie C.
    El-Zoghby, Ziad M.
    Kline, Timothy L.
    Harris, Peter C.
    Czerwiec, Frank S.
    Torres, Vicente E.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (08): : 1153 - 1161
12345